{"changeSha256":"354a7f4dc19a032603f4a676bf5fcdf780363331c75ec44aebbecad8e6264b2f","changedAt":"2026-11-16","changedFields":[{"after":"The generic label cited here describes no trials of its own and states that its trials did not show improvement in symptoms or tumor size. Randomized trials of two other octreotide products, Sandostatin LAR and Mycapssa, are described in their own FDA labels.","before":"The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.","field":"Evidence note"},{"after":"dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531, fda-sandostatin-lar-label-2024, fda-mycapssa-label-2024","before":"dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531","field":"Cited source records"},{"after":"name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-sandostatin-lar-label-2024, fda-mycapssa-label-2024, journal-pmid-2229278, journal-pmid-34953531","before":"name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, journal-pmid-2229278, journal-pmid-34953531","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/octreotide/versions/4/","version":4},"id":"profile:octreotide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section.","peptideSlugs":["octreotide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/octreotide/v3.json","sha256":"f7ab1ae3ce69325bd7313295e4dafd557a147b53a1df57a6ebdbcf8b05c0f17c"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/octreotide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-sandostatin-lar-label-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Sandostatin LAR Depot (octreotide acetate) prescribing information, NDA 021008 supplement S-049, revised July 2024","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf","verifiedAt":"2026-11-16"},{"id":"fda-mycapssa-label-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Mycapssa (octreotide) prescribing information, NDA 208232 supplement S-006, revised July 2024","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208232s006lbl.pdf","verifiedAt":"2026-11-16"}],"subject":{"slug":"octreotide","type":"profile"}}
